Medication info

Linagliptin Duo Tablet 2.5/850 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Seongwon Adcock Pharmaceutical Co., Ltd.
Appearance
Bright orange, biconvex, oval film-coated tablet
Packaging
60 tablets/PTP [10 tablets/PTP packaging x 6]
Approval status
Expired

MFDS item code 202001420 · Approved 2020.02.28

This product's status changed to Expired on 2025.02.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy whose blood glucose cannot be adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose of this medicine should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current dose of metformin (e.g., patients taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current dose of metformin. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). 5. Patients unable to achieve adequate glycemic control with combination therapy with insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current dose of metformin. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral hypoglycemic agent. Caution should be exercised, and appropriate monitoring should be performed, because any change in the treatment regimen for type 2 diabetes may lead to changes in glycemic control. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin. (See Precautions for Use, 1. Do not administer to the following patients).

Ingredients

Manufacturer
Seongwon Adcock Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medication helps improve blood sugar control in adults with type 2 diabetes by assisting dietary therapy and physical exercise. It can be used when patients have not previously used diabetes medications or when blood sugar control is difficult with monotherapy. It is administered in combination with metformin or other medications (sulfonylureas, insulin, empagliflozin, etc.) when blood sugar is not sufficiently controlled, to enhance blood sugar control outcomes. It is prescribed according to individual patient conditions, aiding in the improvement of blood sugar control across various treatment combinations. This medication is effectively used for improving blood sugar control.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy whose blood glucose cannot be adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose of this medicine should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current dose of metformin (e.g., patients taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current dose of metformin. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). 5. Patients unable to achieve adequate glycemic control with combination therapy with insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current dose of metformin. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral hypoglycemic agent. Caution should be exercised, and appropriate monitoring should be performed, because any change in the treatment regimen for type 2 diabetes may lead to changes in glycemic control. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin. (See Precautions for Use, 1. Do not administer to the following patients).

Precautions

This medication contains metformin as one of its main ingredients, which can rarely lead to a serious side effect known as lactic acidosis, hence caution is necessary. It should not be administered to certain patients, for instance, those allergic to the components of this drug, patients with type 1 diabetes, those with severe renal impairment, patients suffering from serious conditions such as acute infections or heart disease, pregnant or breastfeeding women, etc. When taking this medication, attention must be paid to the risk of hypoglycemia, especially if taken together with sulfonylureas or insulin; blood sugar levels should be checked frequently, and dosage adjustments may be necessary. To reduce the risk of lactic acidosis, this medication should be temporarily discontinued in cases of dehydration or situations that may affect renal function, and it is important to notify a doctor immediately if symptoms occur. Renal function is important for the excretion of this medication, so regular renal function tests should be conducted before and during treatment, and it should not be used if renal function is compromised. Patients with poor heart function should use this medication cautiously, particularly those with acute myocardial infarction or heart failure. When undergoing examinations involving radiocontrast agents containing iodine, this medication should be discontinued for a certain period before and after the examination, and it should be resumed only after assessing renal function. It is also necessary to temporarily stop the medication around the time of surgery and may be restarted only after renal function has recovered post-surgery. This medication can rarely cause acute pancreatitis or skin conditions such as bullous pemphigoid, so immediate consultation with a doctor is needed in cases of persistent and severe abdominal pain or the appearance of blisters on the skin. Long-term use may decrease vitamin B12 levels, so if anemia or neurological symptoms occur, blood tests should be conducted to confirm it, and supplementation therapy should be undertaken if required. This medication may interact with other drugs, so it is important to inform the doctor or pharmacist about any other medications being taken for appropriate adjustments. Women who are pregnant or planning to become pregnant should refrain from using this medication, and it should also be avoided while breastfeeding. It is not recommended for children under 10 years of age or adolescents as safety and efficacy have not been established. Elderly patients may experience a decline in renal function, so dosage adjustments and regular monitoring of renal function are necessary. There are no studies on the effects of operating vehicles or machinery; however, caution is required due to the risk of hypoglycemia. In cases of overdose, serious side effects such as lactic acidosis may occur, so immediate hospital treatment is necessary, and if needed, procedures such as hemodialysis should be performed. This medication should be stored out of reach of children, kept dry, and not transferred to other containers.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased vitamin B12 and deficiency
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
Show 116 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • blistering dermatitis
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • upper abdominal pain
  • enterocolitis
  • bowel obstruction
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • dysarthria
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage kidney disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pneumonia
  • hypertension
  • anxiety
  • insomnia
  • depression
  • pruritus
  • delirium
  • nocturia
  • dermatitis
  • erectile dysfunction
  • thyroid goiter
  • increased blood triglycerides
  • decreased hemoglobin
  • increased blood potassium
  • increased blood creatinine
  • increased blood creatine phosphokinase
  • male pattern baldness
  • hyperhidrosis
  • hair loss
  • unstable angina
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • rectal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • gingivitis
  • hypercholesterolemia
  • headache
  • sensory disturbances
  • drowsiness
  • chest discomfort
  • weakness
  • pain
  • nosebleed
  • oropharyngeal pain
  • vocal impairment
  • nosebleed
  • hearing loss
  • benign prostatic hyperplasia
  • thyroid nodule
  • delirium

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. Additionally, when storing the medication, it is advisable to keep it at room temperature, ideally between 1°C and 30°C, avoiding extremes of temperature.

Appearance and packaging

Appearance

Bright orange, biconvex, oval film-coated tablet

Package unit

60 tablets/PTP [10 tablets/PTP packaging x 6]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.